Literature DB >> 19447689

A sensitive and high-throughput LC-MS/MS method for the quantification of pegylated-interferon-alpha2a in human serum using monolithic C18 solid phase extraction for enrichment.

Ziping Yang1, June Ke, Michael Hayes, Matthew Bryant, Francis L S Tse.   

Abstract

The analysis of pegylated-interferon-alpha(2a) in patient serum samples is of high interest for clinic research trials, as this therapeutic protein has become an important antiviral treatment. In this study, an LC-MS/MS method for the absolute quantification of pegylated-interferon-alpha(2a) in human serum was developed. The assay achieved a lower limit of quantification of 3.6 ng/mL (60 pM) with the use of a monolithic C(18) solid phase extraction to enrich the target protein. The linear range of the assay was defined up to 54 ng/mL to measure the typical clinical pegylated-interferon-alpha(2a) levels, and within this range, the precision and accuracy were found to be within +/-20%. The method was applied to a clinical study and found suitable for high-throughput analysis of pegylated-interferon-alpha(2a) in human serum. In addition, further investigations suggested the enrichment step may have general application to the sensitive analysis of other low molecular weight proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19447689     DOI: 10.1016/j.jchromb.2009.04.033

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Direct quantitative analysis of a 20 kDa PEGylated human calcitonin gene peptide antagonist in cynomolgus monkey serum using in-source CID and UPLC-MS/MS.

Authors:  Hongyan Li; Mark J Rose; Jerry Ryan Holder; Marie Wright; Les P Miranda; Christopher A James
Journal:  J Am Soc Mass Spectrom       Date:  2011-06-23       Impact factor: 3.109

Review 2.  Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics.

Authors:  Igor A Kaltashov; Cedric E Bobst; Rinat R Abzalimov; Guanbo Wang; Burcu Baykal; Shunhai Wang
Journal:  Biotechnol Adv       Date:  2011-05-17       Impact factor: 14.227

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.